Empagliflozin
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus. Empagliflozin was approved for medical use in the US and in the European Union in 2014.
SynZeal offers all Empagliflozin related impurities standards with certified COA and characterization data like IR, Mass, HPLC, purity, NMR & TGA report. We also provide CMR, DEPT and detailed structure characterization report as per requirements. Empagliflozin related standards are being used by major pharmaceutical companies across the globe for their ANDA/DMF filing.
